Here’s our fortnightly wrap of all the news driving ASX health stocks.

It’s been a dismal two weeks in the small cap health space, with 80 companies losing ground and just 41 advancing. Another nine were flat.

Code Company Price in cents MktCap % return since Dec 9 % YTD return
ONT 1300 Smiles 680 $ 161,013,011.20 -4 16
1ST 1St Group 3.4 $ 14,012,357.80 -17 -56
4DX 4Dmedical 234 $ 386,757,475.48 3
ACR Acrux 17 $ 28,700,988.99 -3 -11
ACW Actinogen Medical 2 $ 27,564,956.21 -5 -43
1AD Adalta 12 $ 29,421,102.36 -4 5
ADR Adherium 2.6 $ 16,284,817.44 -4 -7
ALC Alcidion Group 18 $ 188,231,869.88 -10 -3
AMT Allegra Orthopaedics 33.5 $ 34,993,833.01 -14 68
ATH Alterity Therap 3.4 $ 64,990,399.30 0 70
AGH Althea Group 42 $ 109,031,755.89 -19 12
ATX Amplia Therapeutics 23.5 $ 24,200,804.70 4 279
ALT Analytica 0.3 $ 10,558,837.00 0 0
ADO Anteotech 10 $ 186,960,486.10 10 364
ANP Antisense Therapeut. 13 $ 71,748,521.38 35 44
APH AP Hemp 31.5 $ 17,386,392.16 -21 75
AHK Ark Mines 3.4 $ 1,778,919.95 0 0
ARX Aroa Biosurgery 110 $ 330,799,055.40 -10
AT1 Atomo Diagnostics 30.5 $ 124,406,552.79 -3
AC8 Auscann Grp Hlgs 18 $ 57,068,524.26 -22 -33
AHC Austco Healthcare 10.5 $ 29,839,839.86 14 14
AVE Avecho Biotech 4.1 $ 28,754,233.56 71 925
BD1 Bard1 Life Sciences 67 $ 52,679,729.52 -12 -34
BNO Bionomics 15 $ 113,963,370.25 15 104
BIT Biotron 7.9 $ 54,048,818.90 -4 52
BXN Bioxyne 1.2 $ 7,681,744.78 0 -14
BOT Botanix Pharma 12 $ 121,642,759.25 -11 46
BPH BPH Energy 3.4 $ 20,333,158.27 3 292
BWX BWX 404 $ 567,944,071.86 -1 -9
CAN Cann Group 53 $ 148,491,957.90 -25 -16
CP1 Cannpal Animal 17 $ 14,900,000.00 -11 42
CAJ Capitol Health 28 $ 287,027,932.80 2 29
CDX Cardiex 5.2 $ 43,560,474.15 4 86
CDY Cellmid 11.5 $ 13,199,791.82 15 -48
CGS Cogstate 110 $ 182,898,705.83 7 182
CMP Compumedics 48.5 $ 80,609,141.34 -1 -39
CBL Control Bionics 100 $ 49,560,740.00 1
CPH Creso Pharma 18.5 $ 133,953,499.23 -38 48
CTE Cryosite 36 $ 16,869,442.68 9 579
CYC Cyclopharm 250 $ 200,686,137.50 -4 113
CYP Cynata Therapeutics 68.5 $ 81,875,946.24 -12 -34
DXB Dimerix 24 $ 37,596,116.43 -4 85
DOC Doctor Care Anywhere 124 $ 220,217,562.87 38
DVL Dorsavi 3.7 $ 11,049,593.05 3 49
EXL Elixinol Global 18.5 $ 45,798,802.51 -36 -62
FFC Farmaforce 9 $ 10,945,533.30 6 -10
GSS Genetic Signatures 203 $ 242,887,068.20 17 97
GTG Genetic Technologies 0.7 $ 66,093,813.94 0 27
GLH Global Health 43.5 $ 18,312,769.20 -1 200
HXL Hexima 17.5 $ 21,065,171.58 -5 -43
HCT Holista CollTech 7.3 $ 19,274,436.09 11 -8
ICS ICSGlobal 212 $ 22,100,439.90 0 13
IDT IDT Australia 17.5 $ 40,515,192.88 -22 25
IBX Imagion Biosys 13.5 $ 129,096,404.97 8 478
IMC Immuron 23.25 $ 53,306,813.91 -1 79
IMM Immutep 39.5 $ 249,051,797.61 41 52
IPD Impedimed 12 $ 134,574,508.75 -11 -25
IMU Imugene 10.5 $ 455,039,195.90 -9 228
IHL Incannex Healthcare 15.5 $ 160,181,988.99 -6 150
ICR Intelicare Holdings 24.5 $ 9,333,811.50 -8
IVX Invion 1 $ 55,370,422.95 -17 -23
JHC Japara Healthcare Lt 61.5 $ 167,029,580.00 -12 -36
JHL Jayex Healthcare 3.8 $ 7,651,794.91 -25 27
KZA Kazia Therapeutics 119 $ 144,460,372.28 -16 107
LBT LBT Innovations 12 $ 33,248,243.86 -14 -25
LSH Lifespot Health 7.7 $ 10,781,879.44 -9 133
LCT Living Cell Tech. 1.6 $ 9,143,055.70 14 0
M7T Mach7 Tech 119 $ 279,282,349.50 0 76
MDR Medadvisor 36 $ 134,718,788.63 -5 1
MEB Medibio 0.9 $ 12,128,963.12 -10 -7
MVP Medical Developments 681 $ 463,259,914.20 -4 -22
MDC Medlab Clinical 24.5 $ 69,918,917.75 -11 -20
MEM Memphasys 13 $ 101,894,473.80 4 160
MXC Mgc Pharmaceuticals 2.5 $ 45,158,055.49 -29 -22
MX1 Micro-X 37 $ 125,769,613.55 6 89
MMJ MMJ Group Hlds 11.5 $ 26,444,708.28 -36 -21
MVF Monash IVF Group 79 $ 307,811,523.60 10 -16
NC6 Nanollose 5.4 $ 6,412,451.13 8 19
NEU Neuren Pharmaceut. 128.5 $ 145,552,297.16 -1 -48
NSB Neuroscientific 26 $ 23,062,786.76 4 37
NTI Neurotech Intl 3.6 $ 18,410,377.46 -33 125
NXS Next Science 128.5 $ 157,759,682.60 5 -32
EYE Nova EYE Medical 34 $ 50,290,148.30 0 -15
NOX Noxopharm 48.5 $ 117,985,784.56 -12 96
NYR Nyrada Inc. 22 $ 16,800,249.40 -6
OSL Oncosil Medical 12.5 $ 104,932,953.50 -7 -25
ONE Oneview Healthcare 4.5 $ 17,663,080.32 -12 -58
OPT Opthea 190 $ 641,561,921.10 -11 -36
OIL Optiscan Imaging 11.5 $ 68,623,984.50 -18 203
OCC Orthocell 44 $ 75,762,652.37 5 -10
OSP Osprey Med Inc 2.1 $ 32,466,939.24 0 -30
OSX Osteopore 51.5 $ 40,189,467.00 -3 -29
OVN Oventus Medical 21 $ 31,652,483.40 -14 -57
PSQ Pacific Smiles Grp 245 $ 376,113,097.50 16 39
PCK Painchek 7.8 $ 89,017,579.12 -7 -59
PAL Palla Pharma 78 $ 91,942,023.21 -2 -26
PAR Paradigm Bio. 245 $ 553,343,642.60 -10 -16
PGC Paragon Care 24.5 $ 76,024,190.70 2 -44
PAB Patrys 2.6 $ 36,159,513.42 37 31
PAA Pharmaust 11 $ 33,230,391.60 -8 2
PXS Pharmaxis 8.4 $ 33,363,103.03 -7 -48
PNV Polynovo 399 $ 2,538,578,088.96 4 103
PTX Prescient 6.3 $ 39,714,286.62 -3 3
PBP Probiotec 229 $ 166,756,880.10 -3 18
PIQ Proteomics Int Lab 81.5 $ 81,826,582.50 12 202
PYC PYC Therapeutics 14.5 $ 459,784,284.94 -3 136
RAC Race Oncology 176 $ 222,510,653.75 -18 826
RCE Recce Pharmaceutical 106 $ 187,608,069.00 -12 194
RGS Regeneus 12 $ 36,034,125.72 -8 38
RAP Resapp Health 8 $ 62,923,917.59 -11 -67
RHT Resonance Health 21.5 $ 98,422,265.26 -23 -4
RSH Respiri 13.5 $ 93,514,302.70 -16 41
RNO Rhinomed 16.5 $ 43,147,552.44 6 -21
RHY Rhythm Biosciences 81 $ 154,144,295.42 -1 612
SDI SDI 79 $ 95,686,751.65 -4 -3
SVA Simavita 1.7 $ 19,615,720.47 6 -32
SOM SomnoMed 200 $ 167,173,816.30 -10 -20
S66 Star Combo 31 $ 43,107,990.08 -14 -36
SCU Stemcell United 1.7 $ 13,143,716.97 -45 21
SUD Suda Pharmaceuticals 3.7 $ 14,191,160.45 -5 -25
TD1 Tali Digital 5 $ 34,468,040.03 9 -2
TLX Telix Pharmaceutical 384 $ 1,087,972,649.36 8 148
THC THC Global Grp 23 $ 46,416,952.51 -19 -39
UBI Universal Biosensors 46 $ 73,670,883.83 7 142
VBS Vectus Biosystems 133 $ 34,820,933.40 -11 125
VTI Vision Tech 2.3 $ 23,849,413.42 -21 -56
VLS Vita Life Sciences.. 98 $ 53,812,198.94 11 52
VHT Volpara Health Tech 138 $ 347,639,267.19 2 -25
ZLD Zelira Therapeutics 9.3 $ 112,605,681.77 -7 69
ZNO Zoono Group 134 $ 210,884,828.50 -9 117

Cannabis companies were among the most volatile shares, represented among both gainers and losers.

Avecho Biotechnology (ASX:AVE) has been the biggest gainer, rising 71 per cent over the fortnight.

AVE shares, which traded around 0.8c from March through to late October, have more than tripled this month, rising as high as 4.5c on Wednesday before closing at 4.1c.

The gains came after Avecho announced yesterday it would join the CA Clinics Observational Study to test the performance of its oral cannabidiol (CBD) products.

CA Clinics hopes to enroll 3000 patients nationwide in its study. They will be surveyed via questionnaire about medicinal cannabis side effects, dosage response, and treatment satisfaction.

The data may well help cannabis products gain greater acceptance – but still, that’s a pretty dramatic share price rise for what amounts to mailing out surveys to cannabis patients.

On the flip side, medical cannabis company Stemcell United (ASX:SCU) has been the biggest loser in the 14-day period (December 9 through December 23).

Its shares spiked from around 1.4c at the start of the month to as high as 4.9c on December 9, but have been mostly in retreat since, closing Wednesday at 1.7c.

The share spike was the subject of two ASX queries.

In its first response, issued December 9, the company said it had no explanation for the recent trading in its securities.

The next day SCU asked for a trading halt and issued a $1.9 million placement at 1.9c a share – a 38.7 per cent discount off their last closing price of 3.1c – to 180 Markets Pty and CS Third Nominees.

In a follow-up letter to the ASX, issued Monday, the company said it only became aware the two parties might be interested in investing in the company the evening of December 9, when its managing director and chief executive received calls from their representatives.

“SCU believes it has promptly and without delay released the information to ASX,” the company said.

The second-biggest loser is Creso Pharma (ASX:CPH), although it was coming off a stellar run in the first part of the month.

CPH shares are down 38 per cent for the fortnight, but are still up by 311 per cent so far for the month.

Another cannabis company, Elixinol Global (ASX:EXL), was the third-biggest loser, dropping 36 per cent.

 

At Stockhead we tell it like it is. While Creso Pharma is a Stockhead advertiser, they did not sponsor this article.